TEVA Stock Recent News
TEVA LATEST HEADLINES
Teva Pharmaceutical Industries reported a smaller than expected rise in first-quarter profit citing higher impairments of tangible assets, while sales of copycat medicines and its branded drugs to treat migraines and Huntington's disease rose.
Teva Pharmaceuticals , and partner Medincell said on Wednesday their experimental schizophrenia drug had met its main goal in a late-stage study.
Evaluate the expected performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 2024 Bank of America Healthcare Conference on Tuesday, May 14, 2024. The presentation will begin at 8:40 A.M. Pacific Time (11:40 A.M. Eastern Time). To access a live webcast of the presentation, visit Teva's Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations. An archived version of the webca.
The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, TEVA and VTRS.
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2024 financial results on Wednesday, May 8, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will b.
Teva Pharmaceutical Industries Ltd. NYSE: TEVA is a global pharmaceutical company in the medical sector specializing in generic and specialty medications.
Teva Pharmaceutical Industries will remain a single company for both generic and branded drugs since generics help to fund research and development of its innovative medicines, Chief Executive Richard Francis said on Tuesday.
Shares of Teva Pharmaceuticals (TEVA) are trending up as the company reported its fourth-quarter earnings, beating Wall Street expectations on both its top and bottom line. On Wednesday, the company confirmed it will sell its active pharmaceutical ingredients business as part of CEO Richard Francis' “pivot to growth” strategy.
Richard Francis, Teva Pharmaceuticals CEO, joins 'Money Movers' to discuss the company's recent divestiture, how easy it'll be to disentangle from part of its business, and more.